When does polatuzumab vedotin’s patent protection expire?
Polatuzumab vedotin (Polivy) is protected by multiple patents, so “the” expiry date depends on which patent (and country) you mean. The provided information does not include any specific patent numbers or jurisdiction-specific expiry dates, so an exact expiry cannot be determined from the question alone.
How do you find the exact expiry date for polatuzumab vedotin in a specific country?
To get a precise date, you typically need:
- The target market (for example, U.S., EU, UK, Canada, Japan).
- The relevant patent family numbers (and whether you’re looking at drug-substance vs. antibody-drug conjugate vs. specific formulations or uses).
- Any regulatory exclusivities that can extend market protection beyond a core patent.
Without the country and patent family details, the best you can do is locate the patent records and map each claim’s expiration.
What could still delay generic or biosimilar entry even after a patent expires?
Even if one patent in the portfolio expires, others can continue to block competition:
- Additional patents covering manufacturing, composition, or use can remain active after the earliest expiration.
- Country-specific regulatory protections (exclusivity periods) can delay approval or marketing.
What to ask next to determine a concrete “patent expiry” date?
If you share either:
- the country (e.g., U.S. or EU), or
- a specific patent number / application number,
I can translate that into the relevant expiry timing for that jurisdiction.
Sources
No sources were provided in the prompt, so I can’t cite specific patent expiry dates.